Rua Bioscience (NZSE:RUA) Debt-to-Equity : 0.02 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Rua Bioscience Debt-to-Equity?

Rua Bioscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NZ$0.04 Mil. Rua Bioscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NZ$0.12 Mil. Rua Bioscience's Total Stockholders Equity for the quarter that ended in Dec. 2023 was NZ$9.48 Mil. Rua Bioscience's debt to equity for the quarter that ended in Dec. 2023 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Rua Bioscience's Debt-to-Equity or its related term are showing as below:

NZSE:RUA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.02 Max: 0.04
Current: 0.02

During the past 3 years, the highest Debt-to-Equity Ratio of Rua Bioscience was 0.04. The lowest was 0.01. And the median was 0.02.

NZSE:RUA's Debt-to-Equity is ranked better than
92.54% of 845 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs NZSE:RUA: 0.02

Rua Bioscience Debt-to-Equity Historical Data

The historical data trend for Rua Bioscience's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rua Bioscience Debt-to-Equity Chart

Rua Bioscience Annual Data

Trend

Jun21

Jun22

Jun23

Debt-to-Equity

0.04

0.03

0.01

Rua Bioscience Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial			0.03	0.03	0.01	0.01	0.02

Competitive Comparison of Rua Bioscience's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Rua Bioscience's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rua Bioscience's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rua Bioscience's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Rua Bioscience's Debt-to-Equity falls into.

Rua Bioscience Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Rua Bioscience's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.047	+	0.068)	/	20.12
	=	0.01

Rua Bioscience's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.044	+	0.124)	/	9.476
	=	0.02

Rua Bioscience (NZSE:RUA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Rua Bioscience Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Rua Bioscience's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Rua Bioscience (NZSE:RUA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rua Bioscience Ltd (NZSE:RUA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Commerce Place, Awapuni, Gisborne, NZL, 4071

Website

https://www.ruabio.com

Rua Bioscience Ltd is a pharmaceutical company engaged in the production of cannabinoid medicines. The company caters to both domestic and international customers. It operates in one segment, being research and development and the sale of pharmaceutical products in Germany and New Zealand.

Rua Bioscience (NZSE:RUA) Headlines

No Headlines